A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

727

Participants

Timeline

Start Date

April 6, 2021

Primary Completion Date

August 31, 2026

Study Completion Date

March 5, 2027

Conditions
Moderate to Severe Upper Facial Lines
Interventions
BIOLOGICAL

IPN10200

"Stage 1: Several different doses will be administrated in a dose-escalation manner.~One single injection will be injected locally into several sites across the glabellar region.~Stage 2: One single injection will be injected locally into several sites across the glabellar, forehead and lateral Canthal regions.~Stage 3: One single injection will be injected locally into several sites across the upper facial area."

BIOLOGICAL

IPN10200 Placebo

"Stage 1: One single injection of study intervention will be injected locally into several sites across the glabellar region.~Stage 2: One single injection will be injected locally into several sites across the glabellar, forehead and lateral Canthal regions.~Stage 3: One single injection will be injected locally into several sites across the upper facial area."

BIOLOGICAL

Dysport

Single administration of study intervention in stage 1 / step 2 and 3 only

Trial Locations (9)

13353

COMPLETED

CRS Clinical Research Services Berlin GMBH, Berlin

Unknown

RECRUITING

MEDITI - Clinique Del Mar, Antibes

RECRUITING

Aimed S.A.S, Lyon

RECRUITING

Clinique de Chirurgie Esthétique Iéna, Paris

ACTIVE_NOT_RECRUITING

Interdisciplinary Study Association, Berlin

RECRUITING

ROSENPARK RESEARCH GmbH, Darmstadt

RECRUITING

Privatpraxis Dr. Hilton & Partner, Düsseldorf

RECRUITING

Fachbereich Chemie Institut für Biologie und Molekularbiologie Studiengang Kosmetikwissenschaft, Hamburg

RECRUITING

Dermatologische Gemeinschaftspraxis Blankenfelde-Mahlow, Mahlow

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY

NCT04821089 - A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines | Biotech Hunter | Biotech Hunter